fluorouracil.... 350 mg/sqm/day IV on days 1 to 5;
and on days 36 to 40.
adriamycin...... 40 mg/sqm IV on days 1 and 36.
semustine....... 150 mg/sqm orally on day 1.
FREQUENCY....... Repeat cycle every 10 weeks.
Anonymous. Phase II-III chemotherapy studies in advanced
gastric cancer. The Gastrointestinal Tumor Study Group. Cancer
Treatment Reports. 63(11-12):1871-6, 1979 Nov-Dec.
In this multi-institutional study of advanced gastric
cancer, 141 eligible and evaluable patients were treated with
either (a) Adriamycin alone, (b) a combination of
5-fluorouracil, Adriamycin, and methyl-CCNU (FAMe), or (c) a
combination of 5-fluorouracil, mitomycin C, and cytosine
arabinoside (FMC). In patients with measurable disease and no
prior chemotherapy, objective responses were seen in four of
17 patients (24%) receiving Adriamycin alone, in seven of 15
(47%) receiving FAMe, and in three of 18 (17%) receiving FMC.
In previously treated patients with measurable disease,
objective responses were seen in three of 17 patients (18%)
receiving Adriamycin alone and in one of 11 (9%) receiving
FMC. In previously untreated patients with both measurable and
nonmeasurable disease, FAMe showed a significant advantage
over both Adriamycin alone and FMC with regard to interval to
disease progression and survival. In comparing Adriamycin
alone with FMC in previously treated patients, intervals to
disease progression and survival were essentially identical.